What an Institutional Review Board Does in Clinical Research

By the Regenerative Evidence Guide Team

What an Institutional Review Board does, in plain terms

An Institutional Review Board (IRB) is a federally required committee that reviews human-subjects research before it starts, with authority to approve, modify, or reject a study. Seeing “IRB-approved” on a clinic site is common — but it does not mean a treatment works, only that the study’s design and consent process were reviewed for safety.

IRBs review the study protocol itself, along with related materials such as the informed consent form and any documents given to participants. That review is not an evaluation of whether a regenerative-medicine product or procedure is likely to help you — that’s a separate question, covered in How We Research.

Where does an IRB’s oversight authority come from?

Modern human-research protections trace back to the Nuremberg Code of 1947 and the Declaration of Helsinki of 1964, both written in response to research abuses. In the United States, a series of publicized harms led Congress to pass the National Research Act of 1974, which created a national commission to define ethical ground rules for research.

That commission published the Belmont Report in 1978. It set out three principles that still guide IRB decisions today:

Respect for persons — participants must be treated as capable of making their own informed choice, with extra protection for people who cannot fully consent for themselves.
Beneficence — researchers must work to maximize possible benefit and minimize possible harm.
Justice — the burdens and benefits of research should be distributed fairly, so no single group bears the risk while another gets the benefit.

These principles were later written into federal regulation at 45 CFR part 46, often called the “Common Rule” because 15 federal agencies adopted a shared version of it in 1991. This regulation is what requires IRB review for federally funded or federally regulated human research. Our Editorial Policy explains how we verify claims like this against primary sources rather than secondhand summaries.

What happens during IRB review, step by step?

The exact process varies by institution, but the regulatory framework maps out a consistent sequence:

Before recruitment begins. A research team submits a full study protocol, along with the informed consent document participants will be asked to sign.
Group review. The IRB, acting as a committee rather than a single reviewer, evaluates whether risks to participants are minimized and are reasonable compared to any expected benefit, whether the consent process is adequate, and whether the study protects the confidentiality of participants’ data.
One of three outcomes. The IRB can approve the study as submitted, require specific modifications before it can be approved, or disapprove it.
Periodic re-review. Once a study is underway, the IRB does not step away. It conducts continuing review at set intervals and can suspend or terminate its approval if problems arise.
Ongoing records. IRBs are required to keep records of protocols, consent documents, meeting minutes, and any reported problems, which regulators can later inspect.

Who sits on an IRB?

Federal rules require that IRB membership include more than just scientists. Every IRB must include at least one member whose primary expertise is outside the sciences, and at least one member who is not otherwise affiliated with the institution running the study. The intent is to keep the review from becoming a closed conversation among people who all have a stake in the study moving forward.

Does IRB approval mean a treatment is proven safe or effective?

No. This is the part most easily lost in marketing language. IRB approval is not the same as proof that a treatment works, FDA clearance or approval of a drug or device, a commitment that published results will hold up, an endorsement of a specific clinic or product, or a statement that a procedure carries no risk.

Assumption: the treatment is effective. IRB review confirms nothing about effectiveness — only that the study’s design and risk-benefit balance were reviewed. What actually confirms effectiveness: the study’s own published, independently reviewed results, once available.
Assumption: the FDA has approved this treatment. IRB review and FDA approval are separate actions handled by separate bodies. What actually confirms FDA status: a separate FDA regulatory review, not the IRB.
Assumption: the clinic or product is endorsed. The IRB reviews the study protocol, not the clinic’s business or marketing claims. No endorsement exists from IRB review alone.
Assumption: the procedure carries no risk. The IRB confirms risks were minimized and disclosed, not that risk is absent. What actually confirms risk level: the informed consent document’s risk section.

An IRB’s role is procedural and ethical oversight of the research itself. Whether the underlying science holds up is a separate question, one best explored using the frameworks described in Start Here.

Are there extra protections for certain participants?

Federal regulation adds further layers of review for groups considered more vulnerable to pressure or harm in a study setting, including pregnant women, human fetuses, and neonates; prisoners; and children. If a study you’re considering involves one of these groups, then ask specifically whether the IRB applied these additional protections, not just its standard review — a general “IRB-approved” answer is not sufficient for these populations.

What questions should I ask before I enroll?

You can ask a study coordinator or clinic these questions directly. A legitimate research team should be able to answer all of them without hesitation:

Which IRB reviewed this study, and is it registered with the federal Office for Human Research Protections?
Is the IRB independent of the clinic or company running the study, or is it an in-house board?
When was the study’s approval last renewed through continuing review?
Has the IRB ever required changes to the consent form, and if so, what changed?
Who do I contact directly if I have a concern about how the study is being run — separate from the research team itself?

A quick checklist to keep on hand

Print or save this list before your next appointment or consent conversation:

☐ I asked which IRB approved this study and confirmed it is a real, identifiable board.
☐ I understand that IRB approval reviews the study’s conduct, not the treatment’s effectiveness.
☐ I read the informed consent document in full, not just the summary.
☐ I know who to contact with concerns that is separate from the research team.
☐ If I belong to a group with added federal protections, I confirmed those protections were applied.

Frequently asked questions about Institutional Review Boards

What does IRB stand for?

IRB stands for Institutional Review Board — a formally designated committee that reviews and monitors research involving human participants before a study begins and at intervals afterward.

Is IRB approval the same as FDA approval?

No. IRB review and FDA approval are separate regulatory actions carried out by separate bodies. An IRB reviews a study’s design, risks, and consent process; FDA approval is a distinct process that evaluates a specific drug, biologic, or device.

Can anyone serve on an IRB?

Not entirely. Federal rules require every IRB to include at least one non-scientist member and at least one member unaffiliated with the institution running the study, so the review isn’t limited to people with a stake in the outcome.

What happens if an IRB finds a problem with a study already underway?

The IRB can require changes to the protocol or consent process, and it has the authority to suspend or terminate its approval of the study if problems are serious enough.

Do children or pregnant participants get different protections?

Yes. Federal regulation adds specific additional protections for pregnant women, human fetuses and neonates, prisoners, and children, on top of the standard IRB review every study receives.

The limits of what oversight can promise

IRB review reduces certain risks, but it cannot eliminate uncertainty about whether a regenerative-medicine treatment will work for you personally. Even a well-run, properly overseen study can produce results that don’t hold up in later, larger research. Oversight tells you the process was reviewed — it does not tell you the outcome.

When to involve your own doctor

Before enrolling in any study or agreeing to an experimental procedure, discuss it with a physician who is not affiliated with the study team. They can help you weigh the protocol against your specific health history in a way a consent form alone cannot.

This article is for general education and does not provide medical advice, diagnosis, or treatment recommendations. It does not evaluate any specific clinic, product, or study. Speak with a qualified healthcare provider about your individual situation. If you believe your rights as a research participant have been violated, you can contact the study’s IRB directly or file a complaint with the federal Office for Human Research Protections.

Sources: U.S. Department of Health and Human Services, Office for Human Research Protections, 45 CFR 46 FAQs; National Cancer Institute, Dictionary of Cancer Terms, “Institutional Review Board.” Last updated September 9, 2026, by the Regenerative Evidence Guide Editorial Team.